WELL:XETRA:XETRA-HAN-GINS Indxx Healthcare Megatrend Equal Weight UCITS ETF (EUR)

ETF | Others |

Last Closing

USD 18.17

Change

+0.09 (+0.50)%

Market Cap

N/A

Volume

2.52K

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-09-26 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
XM1D:XETRA Xtrackers MSCI Japan UCITS ETF..

+1.12 (+2.20%)

USD 501.76B
LCUJ:XETRA Lyxor Core MSCI Japan (DR) UCI..

+0.35 (+2.11%)

USD 191.96B
PRAJ:XETRA Amundi Index Solutions - Amund..

+0.53 (+1.97%)

USD 177.46B
PR1J:XETRA Amundi Prime Japan UCITS ETF D..

+0.62 (+2.20%)

USD 177.46B
XDJP:XETRA Xtrackers Nikkei 225 UCITS ETF..

+0.54 (+2.19%)

USD 157.79B
8R80:XETRA Amundi Index Solutions - Amund..

+3.00 (+2.11%)

USD 101.19B
JARI:XETRA Amundi Index Solutions - Amund..

+0.83 (+1.80%)

USD 100.74B
UIM5:XETRA UBS (Lux) Fund Solutions - MSC..

+1.06 (+2.08%)

USD 85.64B
SXR8:XETRA iShares Core S&P 500 UCITS ETF..

-0.72 (-0.13%)

USD 80.38B
FRCJ:XETRA UBS MSCI Japan Socially Respon..

+0.43 (+1.86%)

USD 79.79B

ETFs Containing WELL:XETRA

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 26.16% 94% A 92% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 26.16% 94% A 91% A-
Trailing 12 Months  
Capital Gain 42.67% 94% A 92% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 42.67% 94% A 92% A
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 20.58% 93% A 90% A-
Dividend Return 20.58% 93% A 90% A-
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 23.81% 14% F 25% F
Risk Adjusted Return 86.44% 88% B+ 89% A-
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (EUR)

Quarterly Financials (EUR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

What to not like:
High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.